Understanding Psoriasis Severity: Links to Systemic Inflammation and Cardiovascular Disease Risk
Recent research links psoriasis severity and systemic inflammation to cardiovascular disease (CVD). The study, led by Axel Svedbom, PhD, from the Karolinska Institutet, reveals that inflammatory signals from the skin can contribute to overall inflammation in the body, potentially increasing the risk of heart issues.
The analysis utilized data from two studies: the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative (PACI) and the Stockholm Psoriasis Cohort (SPC). PACI gathered patients referred by dermatologists in Maryland, while SPC collected data from patients in various Swedish practices. The study involved 260 patients from PACI and 509 from SPC, assessing their psoriasis severity with the Psoriasis Area and Severity Index (PASI) and inflammation levels through a glycan biomarker called GlycA.
Key findings show that higher PASI scores correlated with elevated GlycA levels and cardiovascular risks. The analysis found that PASI scores influenced noncalcified coronary burden and future cardiovascular events. Specifically, direct effects on coronary burden were estimated at 0.94, while indirect effects were 0.19. Odds ratios for the influence of PASI scores on cardiovascular events were 1.23 and 1.16.
The researchers concluded that systemic inflammation, indicated by GlycA levels, may mediate the connection between psoriasis severity and CVD. Future studies should explore if managing psoriasis severity can reduce cardiovascular risks. This research highlights the importance of understanding how skin conditions can affect heart health.
– How does psoriasis severity impact cardiovascular disease risk according to Dr. Axel Svedbom’s research?
Interview: Linking Psoriasis and Cardiovascular Disease – Insights from Dr. Axel Svedbom
NewsDirectory3: We are joined today by Dr. Axel Svedbom, lead researcher from the Karolinska Institutet, to discuss recent findings on the relationship between psoriasis severity, systemic inflammation, and cardiovascular disease (CVD). Dr. Svedbom, thank you for being with us today.
Dr. Svedbom: Thank you for having me.
NewsDirectory3: Your recent study highlighted a concerning link between psoriasis and cardiovascular health. Can you explain what prompted this research?
Dr. Svedbom: We have long known that psoriasis is not just a skin condition; it has systemic implications. The hypothesis driving our research was that the inflammatory signals arising from the skin could be contributing to systemic inflammation, which is a known factor in cardiovascular disease. We wanted to investigate this connection more thoroughly.
NewsDirectory3: You utilized data from two significant studies: PACI and SPC. Can you give us an overview of these data sets?
Dr. Svedbom: Absolutely. The Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative (PACI) gathered data from 260 patients referred by dermatologists in Maryland, while the Stockholm Psoriasis Cohort (SPC) involved 509 patients treated in various Swedish practices. By analyzing this extensive data, we hoped to better understand how psoriasis severity correlates with systemic inflammation and heart health.
NewsDirectory3: Your research employed the Psoriasis Area and Severity Index (PASI) and a biomarker called GlycA. How did these tools help your study?
Dr. Svedbom: The PASI score allows us to quantify the severity of psoriasis in patients, while GlycA serves as a sensitive marker for systemic inflammation. By correlating these measures, we could see not only how severity impacts inflammation levels but also how these levels relate to cardiovascular risks.
NewsDirectory3: What were the key findings of your study regarding the relationship between PASI scores and cardiovascular risk?
Dr. Svedbom: We observed a significant correlation: higher PASI scores were associated with elevated GlycA levels and increased cardiovascular risks. Notably, the PASI scores influenced noncalcified coronary burden and future cardiovascular events, with odds ratios showing a clear risk association. Specifically, the scores had direct effects quantified at 0.94 and indirect effects at 0.19.
NewsDirectory3: That’s compelling evidence. Can you elaborate on the implications of these findings for patients with psoriasis?
Dr. Svedbom: Our research suggests that systemic inflammation, as indicated by GlycA levels, may mediate the relationship between psoriasis severity and cardiovascular disease. This means that managing and treating psoriasis effectively may potentially mitigate some of the cardiovascular risks associated with its severity.
NewsDirectory3: What future research do you envision in this area?
Dr. Svedbom: Future studies should focus on whether reducing psoriasis severity directly lowers cardiovascular risk. This could open new avenues for treatment strategies that not only address skin health but also consider heart health.
NewsDirectory3: Do you have any final thoughts for our readers regarding the link between psoriasis and cardiovascular disease?
Dr. Svedbom: It’s crucial to recognize that skin conditions like psoriasis are not isolated but can influence overall health significantly. Awareness and proactive management may help patients prevent further complications, including cardiovascular disease.
NewsDirectory3: Thank you, Dr. Svedbom, for your valuable insights on this important topic. We appreciate your time and your contributions to advancing our understanding of psoriasis and heart health.
Dr. Svedbom: Thank you for having me.
References:
1. Svedbom A, Mallbris L, González-Cantero Á, et al. Skin Inflammation, Systemic Inflammation, and Cardiovascular Disease in Psoriasis. JAMA Dermatol. Published online November 20, 2024.
2. Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018.